Updated January 3, 2022
Excellent article by Steve Kirsch details, “How Elsevier manipulates peer-reviewed science to match the narrative”.
Access the Full Steve Kirsch Article here
December 24, 2021
Dr. Peter McCullough explains the review process, how he and Jessica Rose’s peer-reviewed VAERS analysis was retracted by Elsevier, the publisher.
He states, “Elsevier is going to be absolutely slaughtered on this. I can make that a promise.”
Access the Most Recent Video from Dr. McCullough here
November 17, 2021
Access Dr. Peter McCullough Elsevier Lawsuit Announcement here
Access Dr. Rose Interview on censored paper here
October 22, 2021
A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products
Access the full article here when elsevier awakens…
According to blog Retraction Watch, a paper co-authored by Dr. Peter McCullough and Jessica Rose has earned a “temporary removal” — without any explanation from the publisher. The co-author of the paper, Jessica Rose reported to Retraction Watch, “the publisher had applied the temporary withdrawal label to the paper without informing us. The publisher claimed that since ‘it wasn’t an invited paper’ that they were reconsidering publishing it and hence the ‘temporary withdrawal. Rose said the move was “unheard of” and that Elsevier was “breaching the contract we signed – all fees have been paid for gorgeous color graphics.”
Elsevier explains on website Policy “Article removal: legal limitations, in an extremely limited number of cases, it may be necessary to remove an article from the online database. This will only occur where the article is clearly defamatory, or infringes others’ legal rights, or where the article is, or we have good reason to expect it will be, the subject of a court order, or where the article, if acted upon, might pose a serious health risk. In these circumstances, while the metadata (Title and Authors) will be retained, the text will be replaced with a screen indicating the article has been removed for legal reasons”.
The Abstract of the soon to be PUBLISHED paper:
Abstract
“Following the global rollout and administration of the Pfizer Inc./BioNTech BNT162b2 and Moderna mRNA-1273 vaccines on December 17, 2020, in the United States, and of the Janssen Ad26.COV2.S product on April 1st, 2021, in an unprecedented manner, hundreds of thousands of individuals have reported adverse events (AEs) using the Vaccine Adverse Events Reports System (VAERS). We used VAERS data to examine cardiac AEs, primarily myocarditis, reported following injection of the first or second dose of the COVID-19 injectable products. Myocarditis rates reported in VAERS were significantly higher in youths between the ages of 13 to 23 (p<0.0001) with ∼80% occurring in males. Within 8 weeks of the public offering of COVID-19 products to the 12-15-year-old age group, we found 19 times the expected number of myocarditis cases in the vaccination volunteers over background myocarditis rates for this age group. In addition, a 5-fold increase in myocarditis rate was observed subsequent to dose 2 as opposed to dose 1 in 15-year-old males. A total of 67% of all cases occurred with BNT162b2. Of the total myocarditis AE reports, 6 individuals died (1.1%) and of these, 2 were under 20 years of age – 1 was 13. These findings suggest a markedly higher risk for myocarditis subsequent to COVID-19 injectable product use than for other known vaccines, and this is well above known background rates for myocarditis. COVID-19 injectable products are novel and have a genetic, pathogenic mechanism of action causing uncontrolled expression of SARS-CoV-2 spike protein within human cells. When you combine this fact with the temporal relationship of AE occurrence and reporting, biological plausibility of cause and effect, and the fact that these data are internally and externally consistent with emerging sources of clinical data, it supports a conclusion that the COVID-19 biological products are deterministic for the myocarditis cases observed after injection”.
Jessica Rose, Peter A. McCullough; TEMPORARY REMOVAL: A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products, Current Problems in Cardiology, 2021, 101011; https://doi.org/10.1016/j.cpcardiol.2021.101011. (https://www.sciencedirect.com/science/article/pii/S0146280621002267)
